MMIT is the market leader in commercial formulary coverage and payer policy intelligence. Medistill covers Medicare + Medicaid drug data (~155M lives), plus the dimensions MMIT doesn't: prescribing by provider, Medicaid utilization by state, drug acquisition cost acquisition costs, compliance screening across 130+ sources, 6B+ negotiated rates, and drug safety signals, all at from $199/mo.
Their strength
Commercial formulary + payer policy
Our strength
Prescribing data + compliance + cost variation
What we add
130+ sources + 6B+ rates + 25M+ adverse-event
Honest positioning
MMIT wins on commercial formulary coverage and payer policy tracking. If your primary need is commercial health plan formulary data across 1,000+ payers or real-time payer policy alerts, MMIT is the better choice. Medistill now covers Medicare + Medicaid (~155M lives) but not commercial employer plans. Where Medistill wins is the broader intelligence layer: Medicaid drug utilization by state, drug acquisition costs, provider-level prescribing, compliance screening, negotiated rate benchmarking, drug safety, and litigation that MMIT doesn't offer.
| Feature | | MMIT (Norstella) |
|---|---|---|
| Core approach | Payer intelligence layer, Medicare + Medicaid drug data (~155M lives), plan formulary coverage, provider compliance, cost variation, prescribing analytics, drug safety, acquisition-cost benchmarks | Formulary and payer policy intelligence platform, commercial + Medicare + Medicaid formulary coverage, restriction analysis, patient access tracking, payer policy alerts |
| Commercial formulary coverage | Not available, Medistill covers plan-level + Medicaid utilization, not proprietary commercial health plan formularies | Core strength, commercial health plan formulary coverage across 1,000+ payers, tier placement, restriction history, and brand vs. generic access scoring |
| plan formulary coverage (1.12M mappings) | 1.12M drug–plan–tier mappings with prior authorization, step therapy, and quantity limits across all plans. Competitive positioning, tier benchmarking, restriction analysis. | plan-level prescribing coverage available as part of payer policy tracking; primary focus is commercial payers |
| Medicaid drug data | 9.3M Medicaid drug utilization rows (2024–2025) across 50 states, prescriptions, units, spending by NDC and state. Utilization data, not formulary PDLs. | Medicaid PDL coverage across all 50 states with preferred/non-preferred status and prior authorization requirements |
| Payer policy tracking | Not available, Medistill does not track commercial payer policy documents, step therapy criteria, or medical policy updates | Core strength, real-time payer policy tracking, medical necessity criteria, step therapy requirements, prior authorization policy changes |
| Competitive access scoring | Formulary tier benchmarking against competing plans; restriction comparisons across Medicare plans | Proprietary access scoring models with brand vs. competitive benchmarking, formulary positioning grades, and access trend analysis |
| drug acquisition costs | 1.6M rows of pharmacy acquisition costs by NDC, updated weekly. Benchmark what drugs actually cost to acquire vs what payers reimburse. | Not available, MMIT tracks formulary positioning, not pharmacy acquisition costs |
| Prescribing data by provider | prescribing data by NPI, volume, cost, drug breakdown by provider, specialty, and geography. Identify outliers and high-cost prescribers. | Not available, MMIT focuses on payer–side formulary and policy data, not provider–level prescribing patterns |
| Provider network intelligence | 2.6M providers at 273K facilities, specialty, address, affiliations, NPI taxonomy. Network gap analysis by geography and specialty. | Not available, MMIT’s focus is formulary and payer policy, not provider network intelligence |
| Provider compliance screening (130+ sources) | Screen providers against 130+ enforcement databases: OIG, SAM.gov, 50 state boards, FDA debarment, NPDB, CMS penalties, court records. Automated risk scoring A–F. | Not available, provider compliance and credentialing screening is outside MMIT’s scope |
| Cost variation (6B+ negotiated rates) | 6B+ negotiated rates from 6,100+ hospital MRFs by payer, procedure, billing code, and hospital. Benchmark what you pay vs. what other payers pay. | Not available, MMIT does not cover hospital negotiated rate benchmarking or price transparency data |
| Drug safety monitoring (25M+ reports) | 25M+ adverse event reports with quarterly trends. Monitor safety signals for formulary drugs. Cross-reference with FDA recalls and enforcement actions. | Not available, pharmacovigilance and adverse event monitoring are outside MMIT’s scope |
| Value-based care analytics | Hospital financials, quality benchmarking, MIPS scores, ACO performance data. Monitor VBC partner stability and quality trends. | Not a primary offering, MMIT focuses on formulary and patient access analytics rather than provider quality or VBC performance |
| Litigation history (10M+ cases) | 10M+ court cases with full opinion text. Litigation history by provider or hospital, malpractice trends, and citation lookup. | Not available |
| Hospital quality benchmarking | CMS Hospital Compare: star ratings, mortality, readmissions, patient safety indicators, HCAHPS across 6,100+ hospitals | Not available, hospital quality benchmarking is outside MMIT’s scope |
| industry-payment data | Every industry payment from pharma/device companies to physicians, by company, product, amount. Cross-reference with prescribing data. | Not available |
| Clinical trials (577K trials) | 577K clinical trials by drug, condition, phase, sponsor, or investigator. Track pipeline drugs that may affect formulary in 2–3 years. | Pipeline tracking available via Norstella’s broader platform; not a core MMIT offering |
| Interface | Ask in any language, get answers in any language. Works on desktop and mobile. Generate custom reports, share with anyone, schedule recurring analyses. API for automation. | Enterprise portal with dashboards, formulary tracking tools, CRM integrations, and territory-level reporting |
| Pricing | from $199/mo unlimited queries | $50K–$200K+/yr |
Use MMIT if:
You need commercial health plan formulary coverage across 1,000+ payers, real-time payer policy and prior authorization tracking, Medicaid preferred drug list monitoring across all 50 states, or proprietary patient access scoring and competitive access benchmarking for brand drugs. MMIT's commercial formulary data is the market standard for pharma market access teams, and it is genuinely valuable for payer teams needing to understand how competitors cover drugs commercially.
Use Medistill if:
You need Medicare + Medicaid drug intelligence (~155M lives), provider-level prescribing data by NPI (not available from MMIT), drug acquisition cost benchmarking, compliance screening across 130+ enforcement sources, negotiated rate benchmarking from 6B+ hospital MRFs, drug safety signal monitoring from 25M+ adverse-event reports, or value-based care partner analytics, all at from $199/mo with no contract required.
Use both if:
Keep MMIT for commercial formulary tracking and payer policy intelligence where their proprietary data is irreplaceable. Add Medistill for provider prescribing analytics, compliance screening, cost variation, and drug safety monitoring, dimensions MMIT does not cover, at from $199/mo alongside your existing MMIT contract.
Pricing
Pro $199 / 500 credits · Business $499 / 1,500 credits · Unlimited $999 ($9,990/yr) · Team from $599/seat
Full access to all 2,000+ datasets. No per-query fees. 1 credit per entity processed.
No credit card required. Expires in 15 days.